#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year) #EULAR2021 @RheumNow https://t.co/xpqhzgeI6q

Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 ⁦@RheumNow⁩ #EULAR2021 ⁦@eular_org⁩ https://t.co/8WCrt11ubV

No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021

SPACING trial OP0138 at #EULAR2021 ⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo) ⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx ⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow

#EULAR Presentation 3478: Infection risk with surgeries: ⭐️Continue conventional DMARD ⭐️Some risk with biologics, may be confounder and no association with timing of infusions ⭐️Steroids are major risk factor! Esp >10 mg/d ⭐️Recommendations shown ⭐️Address other risks! @rheumnow https://t.co/Bi02d4p9Mw

Abst#OP0137 at #EULAR2021: ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) . ➡️This effect becomes evident 2-4 years after tx. @RheumNow https://t.co/GNnYqYmxhl

COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV

• https://ard.bmj.com/content/80/Suppl_1/707.2